USD10
RYTM 股股份
關於 Rhythm PharmaceuticalsRhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
USD10
RYTM 股股份
關於 Rhythm PharmaceuticalsRhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
數據
交易窗口
已關閉
開盤時間
3月24日 at GMT+0 13:30
市值
US$56.49亿
開盤價
沒有足夠的資料
低 (1 年)
US$45.91
高 (1 年)
US$122.20
低 (24 小時)
US$83.53
24 小時高價
US$91.06
成交量（24 小時）
US$38.86万
777,078%
價格歷史記錄
Time | Price | Change |
|---|---|---|
今天 | 沒有足夠的資料 | 沒有足夠的資料 |
1 天 | US$88.88 | |
1 週 | US$89.00 | |
1 個月 | US$97.85 | |
1 年 | US$52.91 |
發現更多
法律
所有證券和投資均由 FINRA/SIPC 會員 Coinbase Capital Markets Corp 提供。證券服務由 Coinbase Capital Markets Corp 提供，與 Coinbase Inc. 提供的數位資產服務、任何關聯公司或 Coinbase Luxembourg S.A. 根據 MiCA 提供的加密資產服務是分開的。SIPC 不適用於您在 Coinbase Inc. 帳戶中持有的數位資產或現金。有關您的經紀商 Coinbase Capital Markets Corp 的其他資訊可在 FINRA 的 BrokerCheck 上找到。所有證券的執行、結算和保管均由 Apex Clearing Corporation 提供。本頁面及其內容僅供參考之用，並不構成投資建議的提供。客戶對其交易活動承擔全部責任，並應就其特定情況諮詢其顧問。本材料並非 (i) 投資、購買或出售任何權益或股份，或參與任何投資或交易策略的要約或招攬，(ii) 旨在提供會計、法律或稅務建議，或投資建議。這些資訊會以截至發行日期當下所能獲得的最新資訊出版，且編撰團隊可能不會更新或是以其他的方式修訂內文資訊，所以在出版日期之後，這裡的資訊可能不會確實反映現實生活中可能會迎來的實際情況與變化。所有投資均涉及風險，且證券或金融產品的過往表現不保證未來的結果或回報。當您投資證券或其他金融產品時，總是有可能虧損。投資人在投資前應仔細考慮其投資目標與風險。接收方應該在做出任何投資決定之前先向他們的顧問諮詢。所有 Ticker 名稱皆為其持有人所屬商標。任何 Ticker 參考並不暗示與第三方有任何從屬關係或得到第三方的認可。並非所有市場的即時報價和/或交易價格都來源於此，來源：那斯達克最後成交。Morningstar 資料 ©2026。
